Options mapped
Appendiceal cancer / pseudomyxoma peritonei: options by country
Sourced options by country plus visit-prep questions for Appendiceal cancer / pseudomyxoma peritonei. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.
Options mappedSolid tumorLast checked June 2026
What this page does
Maps options by country
It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.
What it does not do
Does not choose treatment
It does not rank treatments, recommend a choice, or decide clinical fit.
Where it comes from
Built on trusted sources
Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.
Information to gather before the next visit
- Is the disease localized to the appendix or has it spread within the abdomen/peritoneum?
- Is an appendiceal-cancer specialist or peritoneal-surface malignancy program involved?
- Is the discussion about surgery alone, systemic chemotherapy, HIPEC, or a clinical trial?
- What appendiceal tumor type is documented: neuroendocrine/carcinoid, mucinous neoplasm, adenocarcinoma, goblet-cell, or another subtype?
Trial-search terms to discuss
Options by country
Treatments by country
Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.
United States
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
United Kingdom
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
Sources
- Memorial Sloan Kettering Cancer Center — academic cancer-center treatment information · academic cancer-center treatment information
- National Cancer Institute — national cancer agency rare-tumor information · national cancer agency rare-tumor information
- Cancer Research UK — UK cancer information / guideline-referenced treatment information · UK cancer information / guideline-referenced treatment information
This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.
Beyond approved care
In clinical trials & emerging options
Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.
In clinical trials
- Low-dose versus high-dose HIPEC with mitomycin C; SGN-STNV; fluorouracil with or without mitomycin CClinical trial · NCT06513065Clinical trialTrial only (registry)United Kingdom · PMP HIPEC dose comparison; advanced solid tumors including appendiceal adenocarcinoma/PMP; carcinoma of the appendix/peritoneal cancer chemotherapy context. · One study is recruiting, one terminated, and one has unknown overall status with an old last update. The fibrinogen-concentrate PMP surgery study was fetched but skipped as supportive hemostasis rather than direct anticancer treatment. Confidence/conflicts: High for fetched registry support; medium for current availability due to terminated/unknown-status records and absence of HTA/regulator sources. ClinicalTrials.gov — clinical-trial registry
- Low-dose versus high-dose HIPEC with mitomycin C; SGN-STNV; fluorouracil with or without mitomycin CClinical trial · NCT06513065Clinical trialTrial only (registry)United Kingdom · PMP HIPEC dose comparison; advanced solid tumors including appendiceal adenocarcinoma/PMP; carcinoma of the appendix/peritoneal cancer chemotherapy context. · One study is recruiting, one terminated, and one has unknown overall status with an old last update. The fibrinogen-concentrate PMP surgery study was fetched but skipped as supportive hemostasis rather than direct anticancer treatment. Confidence/conflicts: High for fetched registry support; medium for current availability due to terminated/unknown-status records and absence of HTA/regulator sources. ClinicalTrials.gov — clinical-trial registry
- Low-dose versus high-dose HIPEC with mitomycin C; SGN-STNV; fluorouracil with or without mitomycin CClinical trial · NCT06513065Clinical trialTrial only (registry)United Kingdom · PMP HIPEC dose comparison; advanced solid tumors including appendiceal adenocarcinoma/PMP; carcinoma of the appendix/peritoneal cancer chemotherapy context. · One study is recruiting, one terminated, and one has unknown overall status with an old last update. The fibrinogen-concentrate PMP surgery study was fetched but skipped as supportive hemostasis rather than direct anticancer treatment. Confidence/conflicts: High for fetched registry support; medium for current availability due to terminated/unknown-status records and absence of HTA/regulator sources. ClinicalTrials.gov — clinical-trial registry
- Low-dose versus high-dose HIPEC with mitomycin C; SGN-STNV; fluorouracil with or without mitomycin CClinical trial · NCT06513065Clinical trialTrial only (registry)United Kingdom · PMP HIPEC dose comparison; advanced solid tumors including appendiceal adenocarcinoma/PMP; carcinoma of the appendix/peritoneal cancer chemotherapy context. · One study is recruiting, one terminated, and one has unknown overall status with an old last update. The fibrinogen-concentrate PMP surgery study was fetched but skipped as supportive hemostasis rather than direct anticancer treatment. Confidence/conflicts: High for fetched registry support; medium for current availability due to terminated/unknown-status records and absence of HTA/regulator sources. ClinicalTrials.gov — clinical-trial registry
- HIPEC using mitomycin-C with intraoperative blood and peritoneal-fluid samplingClinical trial · NCT05513183Clinical trialTrial only (registry)Korea · HIPEC using mitomycin-C in peritoneal-metastasis/appendiceal neoplasm/PMP context. · This is a completed safety/toxicity study and does not test antitumor efficacy or establish a treatment recommendation. Confidence/conflicts: High for the Korea-site safety-study record; low for treatment availability beyond the research context. ClinicalTrials.gov — clinical-trial registry
- HIPEC using mitomycin-C with intraoperative blood and peritoneal-fluid samplingClinical trial · NCT05513183Clinical trialTrial only (registry)Korea · HIPEC using mitomycin-C in peritoneal-metastasis/appendiceal neoplasm/PMP context. · This is a completed safety/toxicity study and does not test antitumor efficacy or establish a treatment recommendation. Confidence/conflicts: High for the Korea-site safety-study record; low for treatment availability beyond the research context. ClinicalTrials.gov — clinical-trial registry
- HIPEC using mitomycin-C with intraoperative blood and peritoneal-fluid samplingClinical trial · NCT05513183Clinical trialTrial only (registry)Korea · HIPEC using mitomycin-C in peritoneal-metastasis/appendiceal neoplasm/PMP context. · This is a completed safety/toxicity study and does not test antitumor efficacy or establish a treatment recommendation. Confidence/conflicts: High for the Korea-site safety-study record; low for treatment availability beyond the research context. ClinicalTrials.gov — clinical-trial registry
- HIPEC using mitomycin-C with intraoperative blood and peritoneal-fluid samplingClinical trial · NCT05513183Clinical trialTrial only (registry)Korea · HIPEC using mitomycin-C in peritoneal-metastasis/appendiceal neoplasm/PMP context. · This is a completed safety/toxicity study and does not test antitumor efficacy or establish a treatment recommendation. Confidence/conflicts: High for the Korea-site safety-study record; low for treatment availability beyond the research context. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC contextClinical trial · NCT05472948Clinical trialTrial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC contextClinical trial · NCT05472948Clinical trialTrial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC contextClinical trial · NCT05472948Clinical trialTrial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC contextClinical trial · NCT05472948Clinical trialTrial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC contextClinical trial · NCT05472948Clinical trialTrial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC)Clinical trial · NCT03210298Clinical trialTrial only (registry)Russia · Peritoneal malignancy/PIPAC registry including appendix cancer and PMP. · Overall status is unknown despite recruiting site statuses in the fetched location text. The registry includes many tumor types and does not by itself demonstrate appendiceal/PMP-specific outcomes. Confidence/conflicts: Medium-high for listed country sites and condition inclusion; low for current access because overall status is unknown and no regulator source was fetched. trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC)Clinical trial · NCT03210298Clinical trialTrial only (registry)Russia · Peritoneal malignancy/PIPAC registry including appendix cancer and PMP. · Overall status is unknown despite recruiting site statuses in the fetched location text. The registry includes many tumor types and does not by itself demonstrate appendiceal/PMP-specific outcomes. Confidence/conflicts: Medium-high for listed country sites and condition inclusion; low for current access because overall status is unknown and no regulator source was fetched. trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC)Clinical trial · NCT03210298Clinical trialTrial only (registry)Russia · Peritoneal malignancy/PIPAC registry including appendix cancer and PMP. · Overall status is unknown despite recruiting site statuses in the fetched location text. The registry includes many tumor types and does not by itself demonstrate appendiceal/PMP-specific outcomes. Confidence/conflicts: Medium-high for listed country sites and condition inclusion; low for current access because overall status is unknown and no regulator source was fetched. trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.